title: Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses.
abstract: Following the discovery of the hepatitis C virus (HCV) more than 25 years ago the field has succeeded to develop methods that have changed the safety of blood products, understand the molecular virology, epidemiology and clinical disease of HCV, and identify specific targets for the development of direct-acting antivirals for HCV cure. Nevertheless, major clinical and scientific challenges remain: therapy is still only available to a fraction of infected patients worldwide and many patients remain undiagnosed and/or live in countries where therapy is unattainable. An urgently needed HCV vaccine to eradicate infection remains still elusive. Scientifically, major questions remain regarding the life cycle, pathogenesis and mechanisms of viral clearance and persistence. Addressing these challenges, this meeting report reviews key findings of the 22nd International Symposium on Hepatitis C Virus and Related Viruses in Strasbourg, France from October 9 to 13, 2015.
authors.affiliation: Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, France; Université de Strasbourg, France; Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Electronic address: Thomas.Baumert@unistra.fr.
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Baumert
authors.affiliation: Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, France; Université de Strasbourg, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Schuster
authors.affiliation: CIRI - International Center for Infectiology Research, Lyon, France; Inserm, U1111, Lyon, France; Ecole Normale Supérieure, CNRS UMR 5308, Lyon, France; LabEx Ecofect, University of Lyon, Lyon, France.
authors.forename: François-Loïc
authors.initials: FL
authors.lastname: Cosset
authors.affiliation: University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection & Immunity of Lille, F-59000 Lille, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Dubuisson
authors.affiliation: University Hospital Freiburg, Department of Medicine, Clinic for Medicine II, Freiburg, Germany.
authors.forename: Maike
authors.initials: M
authors.lastname: Hofmann
authors.affiliation: University of Lübeck, Institute for Virology und Cell Biology, Germany.
authors.forename: Norbert
authors.initials: N
authors.lastname: Tautz
authors.affiliation: Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, France; Université de Strasbourg, France.
authors.forename: Mirjam B
authors.initials: MB
authors.lastname: Zeisel
authors.affiliation: University Hospital Freiburg, Department of Medicine, Clinic for Medicine II, Freiburg, Germany.
authors.forename: Robert
authors.initials: R
authors.lastname: Thimme
mesh_terms: D056704:Adaptive Immunity; D016174:Hepacivirus / Q000235:genetics / Q000502:physiology*; D006526:Hepatitis C / Q000150:complications / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D008113:Liver Neoplasms / Q000209:etiology; D014761:Viral Hepatitis Vaccines / Q000276:immunology; D019065:Virus Assembly; D053586:Virus Internalization; D014779:Virus Replication
chemical_list: D014761:Viral Hepatitis Vaccines
keywords: Hepatitis C virus; Immune responses; Liver disease; Meeting report; Molecular virology; Resistance; Therapy; Treatment; Vaccine; Viral hepatitis; Virus